

Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies

Mohammad Saeid Rezaee Zavareh^{1,2} and Seyed Moayed Alavian^{2,3*}

¹Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

²Middle East Liver Diseases Center, Tehran, IR Iran

³Baqiyatallah Research Center for Gastroenterology and Liver Disease (BRCL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran

*Corresponding Author: Seyed Moayed Alavian, Middle East Liver Diseases Center, Tehran, IR Iran. Tel: +98-2188945186, Fax: +98-2188945188, E-mail: Editor@Hepatmon.com

Received 2015 September 28; Accepted 2015 October 4.

Keywords: Hepatitis C, Therapy, Infection Control, Recurrence

1. Hepatitis C Virus Infection, a Global Concern

Hepatitis C Virus (HCV), as the only member of genus Hepacivirus within the family of Flaviviridae, is the major worldwide health concern. Diagnosis of HCV infection is based on finding antibodies against the virus (HCV-antibodies) or HCV-RNA in the serum (1). It is known that some of the recently infected patients can recover from the acute infection. A meta-analysis of almost 700 patients with acute HCV-infection showed that the range of spontaneous viral clearance is about 26% (95% confidence interval 22% - 29%) (2). However, the remaining patients can develop Chronic Hepatitis C (CHC) infection that affects about 3% of world population, related to more than 170 million people all over the world. Chronic hepatitis C can lead to liver fibrosis and cirrhosis and finally Hepatocellular Carcinoma (HCC) in about 20% of cases. It is estimated that about 500000 deaths per year is related to CHC (3). On the other hand, in the acute phase of HCV infection, some patients stay unrecognized. These individuals can make transmission of HCV to other people by some high-risk behaviors like IV drug abuse, organ donation and blood transfusion (4). Now think about a condition that CHC cannot be diagnosed with the mentioned routine diagnostic tests and Imagine about dimensions of this condition on the health status of society.

2. Occult Hepatitis C Virus Infection and Its Clinical Significance

About eleven years ago a new type of CHC infection, Occult Hepatitis C Infection (OCI), was introduced. It means finding of HCV-RNA in the hepatocytes in the absence of serum HCV-RNA that is checked by aforementioned usual tests (5). The most precise method for diagnosis of OCI is checking the presence of HCV-RNA in the liver cells by liver biopsy. Occult hepatitis C infection seems to be milder

than CHC. However, the literature has some evidences that show it can lead to liver cirrhosis and ultimately HCC (6). On the other hand, OCI has been reported in some high-risk population groups like hemodialysis and kidney transplanted patients, cryptogenic liver disease, and immunodeficient patients. Furthermore, some data suggest existence of OCI among healthy subject without liver disease and even spouse and family members of OCI infected patients. Hence, using of an alternative diagnostic method, instead of invasive procedure of liver biopsy seems to be reasonable. These suggested alternative methods are checking HCV-RNA in ultracentrifuged serum and in peripheral blood mononuclear cells (PBMCs) that can lead to diagnosis of about 57% and 61% of OCI infected patients, respectively. Also, it is said that using of both methods can help to find about 91% of these patients (7, 8). Studies showed that HCV genotypes 1 through 4 are involved in the OCI. This may indicate that OCI is a probable worldwide issue. More prevalence studies are still needed to investigate this topic (1, 9).

3. New Treatment Regimens and Occult Hepatitis C Infection

Recently, recommended treatment regimens for HCV infection have been led to a revolution in its treatment. Among them introducing Sofosbuvir, a nucleotide analogue inhibitor, opened new horizons for HCV treatment. (10) Adding Sofosbuvir to the peg-interferon pulls ribavirin regimen has showed an effective and safe result for HCV treatment (11). In addition, it is reported that combination of sofosbuvir with ledipasvir can result in high rate of Sustained Virological Response (SVR) among both treatment-naive and treatment-experienced patients infected with genotype 1-HCV (12, 13). This suggests a successful noninterferon-based therapy for HCV.

Because of OCI related complications, its treatment

seems necessary. On the other hand, some data showed that eradication of OCI cannot be achieved in all patients. However, data regarding OCI treatment are still very limited (14). To the best of our knowledge, there are two studies about this important issue and both of them recommended that interferon-based antiviral therapy can be useful in OCI treatment (15, 16).

4. Conclusions

We address important issues here and they should be considered in future studies. The first point is related to the effect of new treatment regimens on the patients with OCI and the second point is related to remaining the HCV infection as OCI after therapy with new regimens. Some data reported that spontaneous relapse due to OCI should be considered even after existence of 24 weeks of SVR (17). Perhaps new treatment regimens kill this 11 year-old kid of HCV infection forever but HCV-RNA can persist in immune cells and liver tissue (14) and therefore as a reason for relapse, we recommend that some original studies be performed to evaluate the effect of recently suggested treatment on the OCI. On the other hand, we probably need some studies that investigate the existence of HCV-RNA in BMCs and in liver cells, after successful treatment of HCV-infected patients with new regimens.

References

1. Carreno V, Bartolome J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. *World J Gastroenterol*. 2012;**18**(23):2887-94. doi: 10.3748/wjg.v18.i23.2887. [PubMed: 22736911]
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *J Viral Hepat*. 2006;**13**(1):34-41. doi: 10.1111/j.1365-2893.2005.00651.x. [PubMed: 16364080]
3. Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. *World J Hepatol*. 2015;**7**(17):2100-9. doi: 10.4254/wjh.v7.i17.2100. [PubMed: 26301052]
4. Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. *Expert Rev Anti Infect Ther*. 2009;**7**(3):351-61. doi: 10.1586/eri.09.8. [PubMed: 19344247]
5. Bokharaei-Salim F, Keyvani H, Monavari SH, Alavian SM, Madjd Z, Toosi MN, et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. *J Med Virol*. 2011;**83**(6):989-95. doi: 10.1002/jmv.22044. [PubMed: 21503911]
6. Rezaee Zavareh MS, Alavian SM, Karimisari H, Shafiei M, Saiedi Hosseini SY. Occult hepatitis C virus infection in patients with autoimmune hepatitis. *Hepat Mon*. 2014;**14**(8):e16089. doi: 10.5812/hepatmon.16089. [PubMed: 25337141]
7. Rezaee-Zavareh MS, Ramezani-Binabaj M, Moayed Alavian S. Screening for occult hepatitis C virus infection: Does it need special attention? *Hepatology*. 2015;**62**(1):321-2. doi: 10.1002/hep.27626. [PubMed: 25476196]
8. Gatsrelia L, Sharvadze L, Karchava M, Dolmazashvili E, Tsertvadze T. Occurrence of occult HCV infection among HIV-infected patients in Georgia. *Georgian Med News*. 2014;**226**(2):37-41. [PubMed: 24523330]
9. Youssef SS, Nasr AS, El Zanaty T, El Rawi RS, Mattar MM. Prevalence of occult hepatitis C virus in Egyptian patients with chronic lymphoproliferative disorders. *Hepat Res Treat*. 2012;**2012**:429784. doi: 10.1155/2012/429784. [PubMed: 23304473]
10. Alavian SM. Sofosbuvir has come out of the magic box. *Hepat Mon*. 2013;**13**(12):e16916. doi: 10.5812/hepatmon.16916. [PubMed: 24358046]
11. Pol S, Sulkowski MS, Hassanein T, Gane EJ, Liu L, Mo H, et al. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. *Hepatology*. 2015;**62**(1):129-34. doi: 10.1002/hep.27836. [PubMed: 25847509]
12. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med*. 2014;**370**(20):1889-98. doi: 10.1056/NEJMoa1402454. [PubMed: 24725239]
13. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med*. 2014;**370**(16):1483-93. doi: 10.1056/NEJMoa1316366. [PubMed: 24725238]
14. Rezaee-Zavareh MS, Einollahi B. Treatment of occult hepatitis C virus infection: does it need special attention? *Hepat Mon*. 2014;**14**(7):e16665. doi: 10.5812/hepatmon.16665. [PubMed: 25067939]
15. Casato M, Lilli D, Donato G, Granata M, Conti V, Del Giudice G, et al. Occult hepatitis C virus infection in type II mixed cryoglobulinaemia. *J Viral Hepat*. 2003;**10**(6):455-9. [PubMed: 14633180]
16. Pardo M, Lopez-Alcorocho JM, Castillo I, Rodriguez-Inigo E, Perez-Mota A, Carreno V. Effect of anti-viral therapy for occult hepatitis C virus infection. *Aliment Pharmacol Ther*. 2006;**23**(8):1153-9. doi: 10.1111/j.1365-2036.2006.02886.x. [PubMed: 16611276]
17. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? *Hepatology*. 2009;**49**(2):665-75. doi: 10.1002/hep.22706. [PubMed: 19105211]